It is found that the activity of CD11b protein is closely related to the development of cancer

In the face of cunning cancer, human beings obviously do not have enough means to prevent it from spreading in the body But researchers at Rush University and the University of California, San Diego, have just found a new intervention to prevent immune cells from being hijacked by malignant tumors and help them grow and metastasize Bone marrow cells are white blood cells that patrol the body looking for pathogens Previous studies have found that there are two subtypes of M1 macrophage, which can inhibit tumor growth, while M2 does the opposite
Vineet Gupta, senior coauthor of the study (from Rush University) M2 can resist the "infantry" (beneficial T cells) of the immune system and actively assist in the growth and spread of cancer This new study, introduced in this paper, reveals the important clues that bone marrow cells become macrophages (or other macrophages) The key is a protein called CD11b, which exists on the surface of bone marrow cells When CD11b activity increased, the number of M1 myeloid cells also increased When CD11b becomes less, more M2 cells will develop Tumor cells will take advantage of this feature (active inhibition of proteins) to produce more M2 cells, thus promoting their own growth With the disclosure of this mechanism, researchers conducted follow-up experiments to determine whether CD11b might be a potential target for cancer treatment They designed a mouse that was completely deficient in the protein and then transplanted the tumor into it The results showed that compared with the control group, the tumor of the experimental mice would grow larger Next, the team tried reverse engineering They introduced a molecule called leukadherin-1 (LA-1) to normal mice to enhance the function of CD11b protein The results showed that the tumor was significantly reduced Research diagram - 2 (from nature Communications) Finally, in order to verify the actual effect of this protein, the researchers designed a mouse that always has the activity of CD11b protein Normal mice can only occasionally show the activity of CD11b protein, but it has been proved that the tumor of mice that are always activated will also shrink dramatically This technology is expected to become a new way to cure human cancer in the future, but it needs to be further studied for many years before entering clinical trials Details of the study have been published in the recently published journal Nature communications Original title: integrity CD11b activation drives anti tumor intrinsic immunity